Maia Biotechnology (MAIA) plans to start enrollment of certain patients resistant to checkpoint inhibitors and chemotherapy in a phase 3 study of THIO-104 for non-small lung cancer in H2.
The trial will evaluate the efficacy of THIO-104 administered in sequence with a checkpoint inhibitor to improve the overall survival of patients whose cancer has continued to grow after two previous lines of systemic treatment, the company said Thursday in a statement.
The study will enroll up to 300 patients in Asia, Europe and the US to compare the treatment with chemotherapy in 1-to-1 randomization, the company said.
Price: 1.85, Change: +0.01, Percent Change: +0.54
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。